Derek Archila has given his Hold rating due to a combination of factors concerning the market dynamics of Apellis Pharmaceuticals’s product Syfovre and its competition with Izervay. The survey ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback